- Home
- LSTA vs GRCE Comparison
LSTA vs GRCE Comparison
Compare LSTA & GRCE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LSTA
- GRCE
- Stock Information
- Founded
- LSTA 1980
- GRCE 2002
- Country
- LSTA United States
- GRCE United States
- Employees
- LSTA N/A
- GRCE N/A
- Industry
- LSTA Misc Health and Biotechnology Services
- GRCE
- Sector
- LSTA Health Care
- GRCE
- Exchange
- LSTA Nasdaq
- GRCE NYSE
- Market Cap
- LSTA 31.2M
- GRCE 30.9M
- IPO Year
- LSTA N/A
- GRCE N/A
- Fundamental
- Price
- LSTA $2.66
- GRCE $3.40
- Analyst Decision
- LSTA Strong Buy
- GRCE
- Analyst Count
- LSTA 1
- GRCE 0
- Target Price
- LSTA $15.00
- GRCE N/A
- AVG Volume (30 Days)
- LSTA 71.7K
- GRCE 72.9K
- Earning Date
- LSTA 02-27-2025
- GRCE 02-14-2025
- Dividend Yield
- LSTA N/A
- GRCE N/A
- EPS Growth
- LSTA N/A
- GRCE N/A
- EPS
- LSTA N/A
- GRCE N/A
- Revenue
- LSTA N/A
- GRCE N/A
- Revenue This Year
- LSTA N/A
- GRCE N/A
- Revenue Next Year
- LSTA N/A
- GRCE N/A
- P/E Ratio
- LSTA N/A
- GRCE N/A
- Revenue Growth
- LSTA N/A
- GRCE N/A
- 52 Week Low
- LSTA $2.19
- GRCE $2.13
- 52 Week High
- LSTA $4.20
- GRCE $4.97
- Technical
- Relative Strength Index (RSI)
- LSTA 42.39
- GRCE N/A
- Support Level
- LSTA $2.45
- GRCE N/A
- Resistance Level
- LSTA $2.95
- GRCE N/A
- Average True Range (ATR)
- LSTA 0.32
- GRCE 0.00
- MACD
- LSTA -0.07
- GRCE 0.00
- Stochastic Oscillator
- LSTA 17.61
- GRCE 0.00
About LSTA Lisata Therapeutics Inc.
Lisata Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. Its product candidate, LSTA1, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively.
About GRCE GRACE THERAPEUTICS INC
Grace Therapeutics Inc is a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. The company's lead drug candidate, GTx-104, is a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage.